Pittner BT - Search Results

1

An in vitro approach for the characterization of the cycling B cell response.

Pittner BT, Mullins MW, Reid S, Snow EC. Pittner BT, et al. In Vitro Cell Dev Biol Anim. 1998 May;34(5):421-9. doi: 10.1007/s11626-998-0024-y. In Vitro Cell Dev Biol Anim. 1998. PMID: 9639105

2

Strength of signal through BCR determines the fate of cycling B cells by regulating the expression of the Bcl-2 family of survival proteins.

Pittner BT, Snow EC. Pittner BT, et al. Cell Immunol. 1998 May 25;186(1):55-62. doi: 10.1006/cimm.1998.1292. Cell Immunol. 1998. PMID: 9637765

3

CD40-mediated induction of p21 accumulation in resting and cycling B cells.

Mullins MW, Pittner BT, Snow EC. Mullins MW, et al. Among authors: pittner bt. Mol Immunol. 1998 Jul;35(10):567-80. doi: 10.1016/s0161-5890(98)00038-8. Mol Immunol. 1998. PMID: 9823756

4

T helper cell regulation of normal and neoplastic B cell growth.

Snow EC, Pittner B, Reid S. Snow EC, et al. Semin Immunol. 1994 Oct;6(5):311-26. doi: 10.1006/smim.1994.1040. Semin Immunol. 1994. PMID: 7865801 Review.

5

ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype.

Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. Nolz JC, et al. Among authors: pittner bt. Leukemia. 2005 Jun;19(6):1018-24. doi: 10.1038/sj.leu.2403726. Leukemia. 2005. PMID: 15800671

6

CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation.

Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. Pittner BT, et al. Leukemia. 2005 Dec;19(12):2264-72. doi: 10.1038/sj.leu.2403975. Leukemia. 2005. PMID: 16208411

7

IL-4 biology: impact on normal and leukemic CLL B cells.

Kay NE, Pittner BT. Kay NE, et al. Among authors: pittner bt. Leuk Lymphoma. 2003 Jun;44(6):897-903. doi: 10.1080/1042819031000068007. Leuk Lymphoma. 2003. PMID: 12854886 Review.

8

CLL B cells with a bimodal CD38 expression pattern: persistence of bimodal populations despite effective therapy for B-CLL.

Pittner BT, Jelinek DF, Kay NE. Pittner BT, et al. Leukemia. 2004 Jan;18(1):180-2. doi: 10.1038/sj.leu.2403151. Leukemia. 2004. PMID: 14523466 No abstract available.

9

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.

Kaufman PA, Neuberger E, Schwartz NRM, Wang S, Liu Y, Hsu LI, Bartley K, Blahna MT, Pittner BT, Wong G, Anders C. Kaufman PA, et al. Among authors: pittner bt. Front Oncol. 2023 Oct 2;13:1264861. doi: 10.3389/fonc.2023.1264861. eCollection 2023. Front Oncol. 2023. PMID: 37849811 Free PMC article.

10

Antimicrobial susceptibility trends among Escherichia coli and Shigella spp. isolated from rural Egyptian paediatric populations with diarrhoea between 1995 and 2000.

Putnam SD, Riddle MS, Wierzba TF, Pittner BT, Elyazeed RA, El-Gendy A, Rao MR, Clemens JD, Frenck RW. Putnam SD, et al. Among authors: pittner bt. Clin Microbiol Infect. 2004 Sep;10(9):804-10. doi: 10.1111/j.1469-0691.2004.00927.x. Clin Microbiol Infect. 2004. PMID: 15355411 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page